IONS vs ALNY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ALNY Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alnylam Pharmaceuticals, Inc. (ALNY) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus ALNY at 15.2x Forward P/E and 19.5% operating margin (+16.7% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against ALNY sits in BREAKDOWN (29th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IONS Revenue | ALNY Revenue | IONS Op. Margin | ALNY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $600M | $70M | -10.2% | -1087.6% | IONS |
| FY2019 | $1.12B | $220M | 32.6% | -427.5% | IONS |
| FY2020 | $730M | $490M | -23.6% | -168.1% | IONS |
| FY2021 | $810M | $840M | -3.7% | -83.9% | IONS |
| FY2022 | $590M | $1.04B | -69.8% | -75.7% | IONS |
| FY2023 | $790M | $1.83B | -44.9% | -15.4% | ALNY |
| FY2024 | $710M | $2.25B | -67.4% | -7.9% | ALNY |
| FY2025 | $940M | $3.71B | -40.4% | 13.5% | ALNY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONS | ALNY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $21.0B | Larger Scale | ALNY |
| Trailing P/E Ratio Valuation | 90.9x | 7.9x | Lower Multiple | ALNY |
| Forward P/E Ratio Valuation | 90.9x | 15.2x | Lower Multiple | ALNY |
| Revenue Growth (YoY) Growth | +54.9% | +16.7% | Higher Growth | IONS |
| Operating Margin (TTM) Profitability | -58.8% | 19.5% | Higher Margin | ALNY |
| Net Profit Margin Profitability | -56.9% | 52.8% | Higher Margin | ALNY |
| Return on Equity (ROE) Capital Efficiency | -108.0% | 138.1% | Higher ROE | ALNY |
| 52-Week Range Position Momentum | 2% ($27โ$87) | 3% ($149โ$477) | Stronger Trend | ALNY |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 86% Vol | 0.54ฮฒ ยท 96% Vol | Lower Realized Risk | IONS |
| Unified Institutional Score Composite Signal | 63.9 / 100 (BUY) | 60.1 / 100 (BUY) | Higher Composite | IONS |